Accessibility links Skip to main content

Key Takeaways from the TCD QP Forum 2025

The Trinity College Dublin QP Forum 2025 brought together leading pharmaceutical quality professionals to explore key industry trends, regulatory updates, and innovation in operational excellence. Here’s a consolidated snapshot of the insights shared by speakers and industry experts.

Contact us

Fill out the form and we will contact you shortly.

Naam
Privacy Policy 
Continue reading
  1. Sustainability and Regulatory Alignment in Pharma

Speakers: Catherine Mulhall, Michael Kilkelly, Brendan Griffen

With growing scrutiny on environmental claims, regulators now demand that pharmaceutical sustainability labels be backed by robust life cycle assessments. Notably, upcoming EU directives will impose levies based on packaging waste to reduce microplastics in water.

Key Takeaways:

  • Manufacturing contributes more to carbon footprint than packaging.
  • Optimising HVAC systems (e.g., feedback loops from particle monitoring) can cut energy usage.
  • Robotics can reduce cleanroom personnel, minimizing contamination and improving sustainability.
  1. Human and Organisational Performance

Presenter: Dermot O’Rourke

Human error is increasingly being framed as a symptom of systemic issues, not individual failure. Dermot emphasized building systems that minimize consequences of mistakes, such as through the use of physical barriers like isolators and RABs.

Cultural Insights:

  • A blame culture suppresses improvement—promote accountability instead.
  • Personnel involved in errors should lead CAPA efforts and share learnings.
  • Encourage questions like: “What almost went wrong today?”
  1. QP in the Digital World

Speaker: Peter Deegan

Transitioning from paper-based processes to digital platforms is reshaping the Qualified Person’s role. With Industry 4.0, the QP becomes a digital champion.

Innovations:

  • AI-driven batch assessments
  • Digital QP dashboards
  • Sensor-based, inline verification
  • Fully integrated Pharmaceutical Quality Systems (PQS) with real-time dashboards
  1. Regulatory Insights from HPRA

Presenter: Paul Sexton

Key updates from HPRA’s 2025 agenda include:

  • Draft revisions to Annex 11 (Computerised Systems) and Chapter 4 (Documentation)
  • Expansion of Mutual Recognition Agreements (MRAs) to include vaccines and plasma-derived products
  • Increased use of hybrid inspections and distant assessments
  • Revised guidance on ATMPs, Annex 1, Annex 14, Annex 16, and new GDP drafting groups

Post-Annex 1 Inspection Focus:

  • Contamination Control Strategy (CCS)
  • Environmental Monitoring
  • Personnel practices
  • Decontamination processes
  1. Releasing Challenging Products

Topics: ATMPs, OOT Batches, Orphan IMPs

Case studies highlighted the ethical and scientific complexity of releasing borderline products.

  • ATMPs: Difficulties in applying GMP to academia-driven therapies using patient cells.
  • OOT Batches: Stability testing decisions must be risk-based and data-supported.
  • Orphan Intrathecals: Low batch frequency requires leveraging data from similar products to support QP release decisions.
  1. Robotic Automation in Aseptic Processing

Presented by Amgen

Amgen demonstrated their pioneering use of collaborative robots (cobots) for tasks like automated tub rejection and sample plate handling post-VHP sterilisation.

Highlights:

  • Gloveless isolators and robotic air sampling systems
  • Compliance with Annex 1 Sections 4.4, 8.9, and 8.16
  • Importance of engaging regulators during innovation
  1. Trending Deviations and Complaints: HPRA Expectations

Speaker: Michael Sreenan

Trending is critical for proactive quality management but often falls short.

Common Deficiencies:

  1. Lack of defined methodology for recurrence checks
  2. Vague or inconsistent search criteria
  3. Poor documentation in deviation records
  4. Ignoring minor incidents which may indicate systemic issues

Best Practices:

  • Define recurrence logic clearly
  • Standardize terminology
  • Include recurrence checks for all investigation levels
  1. Industry Best Practices in Trending

Presenters: Johnson & Johnson & PCI

  • J&J’s COMET system uses structured data fields to reduce variability.
  • Trending includes risk assessment and MA alignment.
  • PCI uses MasterControl with manual trending but aims to automate this process.

 

Conclusion: The Future is Digital, Accountable, and Sustainable

The 2025 TCD QP Forum showcased how the QP role is evolving—from a document reviewer to a digital enabler and strategic risk manager. With regulatory frameworks advancing and technology rapidly transforming operations, staying agile and informed has never been more essential.

 

Your partner in quality, safety, and compliance

The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.

Related services

QP Services

Clinical QP Services

Related articles

07 Apr 2026

MIAS Pharma will be attending the BIO International Convention in San Diego, USA

MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.

01 Apr 2026

Let’s Meet at SNMMI Annual meeting 2026 LA

MIAS Pharma is excited to attend the SNMMI annual meeting in Los Angeles, California, from May 30th – June 2nd 2026. Visit us at booth #1363, we’ll be happy to connect.

20 Mar 2026

Labelling & Packaging: A Core MAH Responsibility

Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.

06 Mar 2026

MAHs: Are Your GMP–GVP Interfaces Aligned?

Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?

27 Feb 2026

MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies

For small and virtual companies, especially those developing rare disease medicines, the requirements of acting as a Marketing Authorisation Holder (MAH) in the EU can feel overwhelming. EU legislation places the MAH at the centre of responsibility for the quality, safety and efficacy of the product throughout its lifecycle, regardless of how many activities are outsourced. MIAS Pharma is designed to be your one integrated partner in Europe: an established presence with the expertise, infrastructure and network to assume day‑to‑day MAH obligations on your behalf while you focus on science, patients and portfolio strategy.

20 Feb 2026

Quality & Regulatory Implications from EU Critical Medicines Act

The European pharmaceutical landscape is entering a period of major regulatory transformation with the introduction of not only the EU Critical Medicines Act (CMA), new pharma package.

28 Jan 2026

Navigating Evolving EU Marketing Authorisation: Are You Ready for Tomorrow’s Compliance?

As the European pharmaceutical landscape transforms, Marketing Authorisation Holders (MAHs) now face a broader – and more demanding – array of duties that stretch far beyond initial product approval. The new compliance reality encompasses critical operational areas like shortage reporting, environmental risk management, end-to-end product data maintenance, supply chain resilience, and more. These obligations often overlap with, yet are legally distinct from, manufacturing and wholesale authorisations – presenting new blind spots and risks for the unprepared.